Ariel Perez (@app1279) header
Ariel Perez (@app1279) profile picture

MD Hematology Oncology BMT Cell Therapy Miami Cancer Center. Former Fellow Moffitt Cancer Center - Views are my own

Miami, FL
Joined December 2013
Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)Photo by Ariel Perez (@app1279)
Ariel Perez retweeted
EPCORE DLBCL-2 Positive RCT Bispecifics to the 1L in DLBCL... HR 0.49 #lymsm #DLBCL #Epcor
5
29
7
123
10,825
Registration is open for the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies 🗓️ Mar 6–7, 2026 bapth.lt/ImmunoSummit #HemeOnc #CART #AML #Lymphoma #MultipleMyeloma
3
5
652
CAR-T in PCNSL #lymsm - 67 pts, 25% CSF+, 12% eye+ - 57% axicel, 30% tisacel - 58% CR, 1-yr PFS 50%, 1-yr OS 66% - 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28% - 27% G3+ ICANS! Almost all got bridging; would love to know which agents. academic.oup.com/neuro-oncol…
1
14
1
26
4,399
But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs! v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500... Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!
3
22
4
61
29,208
I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇 onlinelibrary.wiley.com/shar… 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes. 💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%). 💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity. ❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL 🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X. Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅 👉Please share with your network if you learnt something with this post 🙏 #HemOnc #MedEd #lymphomasm #CARTcelltherapy
1
22
2
56
4,552
Using CARTs for first relapse in myeloma. #mmsm open.substack.com/pub/rafael…
5
10
3
59
9,754
Thank you to @MichaelDJain from @MoffittNews for helping us create this guide and sharing his insights on life after lymphoma. #lymsm
Living with follicular lymphoma can be confusing—especially when you're told to “watch-and-wait.” But many live for decades with few or no symptoms, and go on to lead full lives. Our guide explains why “watch-and-wait” can be safe, and how new treatments offer fresh hope.

3
4
15
1,314
Join Dr Ariel Perez from @MiamiCancerInst in San Juan for a weekend that brings the biggest cancer updates from #ASCO25 straight to Puerto Rico! Don't wait! 👉 Register for free today: totalhealthoncology.com/upco… #ASCODirect25 #CME #MedicalEducation #Oncology @app1279
2
1
321
A study led by Dr. Malpica of our Rare Lymphoma Section found adult T-cell leukemia or lymphoma and extranodal NKT-cell lymphoma are more prevalent among Latin Americans (LA), calling for greater LA participation in global T cell lymphoma research. tinyurl.com/PTCL-Latin
1
10
27
2,087
At #HOPA25 this week to connect, inspire, & recruit amazing pharmacists to join us in sunny Miami! Let’s talk opportunities, growth, and why Baptist Health South Florida might be your next chapter #HOPA2025 #PharmacyJobs #oncopharm tinyurl.com/4zttre85
1
3
185
Ariel Perez retweeted
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial @JuanAlderuccio @TheLancetHaem thelancet.com/journals/lanha…
12
31
1,553
A study finds Melphalan 100 mg/m² with fludarabine reduces GI toxicity and acute/chronic #GVHD compared to 140 mg/m², while maintaining similar non-relapse mortality and overall survival after allogeneic transplantation in #AML and #mdssm. astctjournal.org/article/S26…
23
49
3,603
Real-world sequential BV➡️AVD older cHL #ASH24 @app1279: - 40 pts, med age 72, 48% extranodal - ORR 97% (CR 71%) - 2-yr PFS 63%, OS 83% - 40% dc'd tx (most d/t tox); 15% G2+ PN - 15% loss of ADLs/IADLs Decisions regarding this regimen vs N-AVD. #lymsm cc @HayderSaeed_MD @DrAEvens
3
1
10
2,351
🌟Excited to announce the 14th Annual WCS | Winter Cancer Symposium!🌟 February 28 - March 2, 2025   Rio Grande, Puerto Rico   Register Now! - wintercancersymposium.com @Flendovasc @maryjofidlerMD @blally_md @app1279 @Sonampuri @LuisRaezMD
2
1
3
650
50% of internal medicine residents are IMGs. they are the norm.
This Post is from an account that no longer exists. Learn more
6
21
4
308
106,840
Ariel Perez retweeted
Unexpected use of CD19-CAR-T cells: Point-of-care CD19-directed CAR-T cells in AML expressing CD19. 4/6 patients achieved a CR! @nagler_EBMT @sheba_medical #CART #AML sciencedirect.com/science/ar…
10
1
38
3,854
Our analysis of CAR-T in #PCNSL, CIBMTR N=24; median age 57; 88% active disease; median piror Rx4; ORR 61%; 2yr OS/PFS 50%/28%; NRM 0; CRS 67%; no G3-4. ICANS 33%; 2 with grade or higher. #lymsm #CART @CatherineLeeMD @mshadman @hemant_murthy et al. haematologica.org/haematolog…
1
19
1
71
5,886